COMPASS THERAPEUTICS

Compass Therapeutics to Participate in Upcoming Investor Events

07 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics to Participate in Upcoming Investor Events

30 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

03 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

22 июн 2023 16:05:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics to Participate in Upcoming Investor Events

01 июн 2023 10:06:24 Источник Nasdaq GlobeNewswire

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

04 май 2023 08:30:01 Источник Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

26 апр 2023 08:30:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

19 апр 2023 08:30:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

28 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

15 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

02 фев 2023 08:30:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

19 янв 2023 17:00:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

06 янв 2023 08:30:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

15 дек 2022 08:30:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

01 дек 2022 08:30:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

22 ноя 2022 08:00:01 Источник Nasdaq GlobeNewswire

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

09 ноя 2022 09:00:00 Источник Nasdaq GlobeNewswire

Compass Therapeutics to Present at Upcoming Investment Conferences

08 ноя 2022 08:00:01 Источник Nasdaq GlobeNewswire

Compass Therapeutics Announces $80 Million Private Placement

02 ноя 2022 09:06:54 Источник Nasdaq GlobeNewswire

Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)

11 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire